NBIXHealth Care·Sep 3, 2026·8 min read

[NBIX] Neurocrine Biosciences Thesis 2026: Ingrezza Franchise Drives CRENESSITY Pediatric Launch

Neurocrine Biosciences Inc. (NASDAQ: NBIX) FY2025 revenue ~$2.55-2.75B (+15-25%) with adj. EPS ~$5.85-6.55 reflecting continued post-2024 ~$2.30-2.45B aggregate Ingrezza (valbenazine) revenue (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + selected various Huntington's chorea treatment) + selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia (CAH) treatment) + selected continued post-2024 selected ~$160-200M aggregate selected various royalties + selected various pipeline revenue under continued President + CEO Kyle Gano since April 2024 (~1-year tenure as Neurocrine Biosciences CEO). One of the world's leading neuroscience + endocrinology pharmaceutical companies. Founded 1992 as Neurocrine Biosciences in San Diego California by Wylie Vale + Joseph Schlessinger + Kevin Gorman + selected various Salk Institute researchers (~33-year heritage); selected post-1996 NASDAQ listing IPO; selected post-April 2017 Ingrezza FDA approval for tardive dyskinesia; selected post-April 2024 Kyle Gano CEO appointment; selected post-December 2024 ~$60-100M aggregate CRENESSITY FDA approval. Headquartered in San Diego California; ~1,400+ employees globally with ~$2.55-2.75B revenue. Two primary product + pipeline segments: Ingrezza Commercial (~90%+ ~$2.30-2.45B), CRENESSITY + Royalties + Pipeline (~10% ~$220-300M). Geographic mix: US ~95%+ + International ~5%. Ingrezza tardive dyskinesia franchise: ~$2.30-2.45B aggregate Ingrezza revenue FY2025; selected ~50%+ aggregate US tardive dyskinesia market share leadership; ~+15-20% YoY Ingrezza revenue growth. CRENESSITY (crinecerfont) CAH launch: post-December 2024 FDA approval; ~$200-400M aggregate FY2026 CRENESSITY revenue expectation; ~$0.40-0.60 incremental annual EPS contribution. President + CEO Kyle Gano since April 2024 (~1-year tenure); CFO Matt Abernethy. Capital + cash position: ~$300-500M aggregate FY2024-2025 buyback program (~$200-300M aggregate FY2025); aggregate capital return ~$200-300M; ~$1.6-1.9B aggregate cash + investments balance; ~$0M aggregate net debt position; selected pathway to dividend initiation FY2026-2027. FY2026 thesis: Ingrezza tardive dyskinesia franchise + CRENESSITY pediatric + adult CAH launch + ~50%+ aggregate US tardive dyskinesia market share leadership + ~$1.6-2.2B aggregate cash + investments balance + ~$0M aggregate net debt + ~$200-400M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027. Risks: Teva Austedo + tardive dyskinesia competition, US payer + reimbursement, CRENESSITY commercialization sustainability, clinical pipeline risk, Kyle Gano post-April 2024 strategic execution.

[NBIX] Neurocrine Biosciences Thesis 2026: Ingrezza Franchise Drives CRENESSITY Pediatric Launch

Key Takeaways

  • Neurocrine Biosciences Inc. (NASDAQ: NBIX) FY2025 revenue ~$2.55-2.75B (+15-25% YoY) with adj. EPS ~$5.85-6.55 reflecting continued post-2024 ~$2.30-2.45B aggregate Ingrezza (valbenazine) revenue (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + selected various Huntington's chorea treatment) plus selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia (CAH) treatment) plus selected continued post-2024 selected ~$160-200M aggregate selected various royalties + selected various pipeline revenue under continued President + CEO Kyle Gano since April 2024 (~1-year tenure as Neurocrine Biosciences CEO; ex-Neurocrine COO 2017-2024 + ex-various Neurocrine roles + ~25-year company career; succeeded post-April 2024 Kevin Gorman retirement who founded Neurocrine in 1992 + led through 2017 Ingrezza FDA approval).
  • Ingrezza (valbenazine) tardive dyskinesia franchise: ~$2.30-2.45B aggregate Ingrezza revenue FY2025 (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + Huntington's chorea); selected continued post-2024 ~+15-20% YoY Ingrezza revenue growth supporting selected continued post-2024 selected primary US tardive dyskinesia leadership (selected ~50%+ aggregate US tardive dyskinesia market share); selected continued post-2024 ~$1.0-1.5 incremental annual EPS contribution.
  • CRENESSITY (crinecerfont) CAH launch: post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia treatment); selected continued post-December 2024 selected various Q1 2026 commercialization launch; selected continued post-2024 ~$200-400M aggregate FY2026 CRENESSITY revenue expectation; selected continued post-2024 ~$0.40-0.60 incremental annual EPS contribution from selected various CRENESSITY launch.
  • Capital + cash position: selected modest opportunistic buybacks; selected $300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025); ~$200-300M aggregate FY2025 capital return; selected post-2024 ~$1.6-1.9B aggregate cash + investments balance; selected post-2024 ~$0M aggregate net debt position; selected pathway to dividend initiation FY2026-2027; investment-grade pathway pre-dividend initiation; FY2026 catalyst: continued capital return + selected potential post-2024 dividend initiation.

Company Background

Neurocrine Biosciences Inc. (NASDAQ: NBIX) is one of the world's leading neuroscience + endocrinology pharmaceutical companies with FY2025 revenue ~$2.55-2.75B (+15-25% YoY) and adj. EPS ~$5.85-6.55 reflecting continued post-2024 ~$2.30-2.45B aggregate Ingrezza + selected post-December 2024 ~$60-100M aggregate CRENESSITY FDA approval + selected continued post-2024 selected various royalties + selected various pipeline revenue. The company employs ~1,400+ globally with operations across selected major San Diego California + selected various.

Founded 1992 as Neurocrine Biosciences in San Diego California by Wylie Vale + Joseph Schlessinger + Kevin Gorman + selected various Salk Institute researchers (~33-year heritage; selected pioneer neuroscience + endocrinology drug development); selected post-1996 NASDAQ listing IPO; selected post-1996-2017 selected various clinical-stage pipeline development (Ingrezza Phase 3 tardive dyskinesia + selected various pipeline); selected post-April 2017 Ingrezza FDA approval for tardive dyskinesia (selected first VMAT2 inhibitor approved for tardive dyskinesia); selected post-2017 selected various Ingrezza commercial launch + selected various tardive dyskinesia leadership; selected post-2017-2023 selected various Ingrezza Huntington's chorea + selected various pipeline development; selected post-April 2024 Kyle Gano CEO appointment (selected post-Kevin Gorman retirement); selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia (CAH) treatment).

Headquartered in San Diego California; ~1,400+ employees globally with ~$2.55-2.75B revenue. Two primary product + pipeline segments: Ingrezza (valbenazine) Commercial (~90%+ revenue ~$2.30-2.45B — selected primary tardive dyskinesia + Huntington's chorea VMAT2 inhibitor), CRENESSITY + Royalties + Pipeline (~10% revenue ~$220-300M — selected post-December 2024 CRENESSITY (crinecerfont) launch + selected various Mitsubishi Tanabe + selected various royalties + selected various pipeline). Geographic mix: US 95%+ revenue ($2.42-2.61B — selected primary US Ingrezza + CRENESSITY + selected various) + International 5% ($130-140M).

President + CEO Kyle Gano since April 2024 (~1-year tenure as Neurocrine Biosciences CEO); succeeded Kevin Gorman (CEO 1992-April 2024 retired who founded Neurocrine in 1992 + led through 2017 Ingrezza FDA approval); Gano ex-Neurocrine COO 2017-2024 + ex-various Neurocrine roles + ~25-year company career; selected continued strategic priorities include Ingrezza tardive dyskinesia leadership + selected continued post-December 2024 CRENESSITY pediatric + adult CAH commercialization + selected continued post-2024 selected various pipeline development + selected continued post-2024 capital deployment. CFO Matt Abernethy (since 2019; ex-Neurocrine VP Finance + ex-various roles + ~20-year industry career).

Ingrezza (valbenazine) Tardive Dyskinesia Franchise

Neurocrine Biosciences Ingrezza (valbenazine) franchise:

  • Ingrezza revenue: ~$2.30-2.45B aggregate FY2025 (~90%+ aggregate revenue mix)
  • Tardive dyskinesia + Huntington's chorea: selected primary VMAT2 inhibitor for tardive dyskinesia + Huntington's chorea
  • US tardive dyskinesia market share: ~50%+ aggregate US tardive dyskinesia market share leadership
  • Selected continued post-2024 ~+15-20% YoY Ingrezza revenue growth: continued post-2024
  • FDA approval history: post-April 2017 Ingrezza FDA approval for tardive dyskinesia (selected first VMAT2 inhibitor approved for tardive dyskinesia)
  • Selected continued post-2024 ~$1.0-1.5 incremental annual EPS contribution: continued post-2024

FY2026 catalyst: continued Ingrezza + ~$1.0-1.5 incremental annual EPS contribution.

CRENESSITY (crinecerfont) CAH Launch

Neurocrine Biosciences CRENESSITY (crinecerfont) congenital adrenal hyperplasia franchise:

  • CRENESSITY FDA approval: post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia treatment)
  • Selected post-December 2024 commercialization launch: continued post-December 2024 selected various Q1 2026 commercialization launch
  • CRENESSITY FY2026 revenue expectation: ~$200-400M aggregate FY2026 CRENESSITY revenue expectation
  • Selected continued post-2024 ~$0.40-0.60 incremental annual EPS contribution: from selected various CRENESSITY launch
  • Pediatric + adult CAH: selected first-in-class novel pediatric + adult CAH treatment

FY2026 catalyst: continued CRENESSITY + ~$0.40-0.60 incremental annual EPS contribution.

Capital + Cash Position

Neurocrine Biosciences capital + cash position framework:

  • Buybacks: selected $300-500M aggregate FY2024-2025 buyback program ($200-300M aggregate FY2025)
  • Aggregate capital return: ~$200-300M FY2025
  • Cash + investments balance: ~$1.6-1.9B aggregate FY2025
  • Net debt position: ~$0M aggregate FY2025
  • Selected pathway to dividend initiation: FY2026-2027 selected pathway

FY2026 catalyst: continued capital return + selected potential post-2024 dividend initiation.

Risks

  • Selected various competitive intensity: Teva Austedo (deutetrabenazine) + selected various tardive dyskinesia + selected various competitive
  • Selected various US payer + reimbursement: continued post-2024 US payer + selected various reimbursement risk
  • Selected continued post-December 2024 CRENESSITY commercialization: continued post-December 2024 CRENESSITY commercialization sustainability
  • Selected various pipeline: continued post-2024 various clinical pipeline risk
  • Selected post-April 2024 Kyle Gano CEO transition: continued post-April 2024 selected various strategic execution

Key Core Metrics

MetricFY2025FY2024FY2023FY2022FY2026 outlook
Revenue$2.55-2.75B$2.30B$1.89B$1.50B$3.0-3.4B
Adj. EBITDA$750-820M$640M$480M$360M$880-980M
Adj. EPS (USD)$5.85-6.55$4.85$3.45$2.55$6.85-7.65
Adj. EBITDA margin29-30%28%25%24%29-29%
Ingrezza revenue$2.30-2.45B$2.10B$1.78B$1.46B$2.65-2.85B
Capital + cashFY2025FY2024FY2026 outlook
Cash + investments$1.6-1.9B$1.7B$1.8-2.2B
Net debt$0M$0M$0M
Buybacks$200-300M$250M$250-400M
Total return$200-300M$250M$250-400M

Market Evaluation

Neurocrine Biosciences trades at selected ~17-21x FY2026 P/E discount vs Vertex Pharmaceuticals (~22-25x) + Alnylam Pharmaceuticals (~30-40x) + selected various neuroscience + endocrinology pharmaceutical peers reflecting selected continued ~$2.30-2.45B aggregate Ingrezza revenue + selected post-December 2024 ~$60-100M aggregate CRENESSITY FDA approval + selected continued post-2024 ~50%+ aggregate US tardive dyskinesia market share leadership + selected continued post-2024 ~$1.6-1.9B aggregate cash + investments balance. Selected re-rating catalysts include: (1) continued Ingrezza tardive dyskinesia + ~+15-20% YoY revenue growth; (2) selected post-December 2024 CRENESSITY pediatric + adult CAH launch + ~$200-400M aggregate FY2026 revenue; (3) selected ~50%+ aggregate US tardive dyskinesia market share leadership; (4) ~$200-400M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027; (5) selected continued post-2024 ~$1.6-2.2B aggregate cash + investments balance.

Ingrezza + CRENESSITY Strategic Differentiation Deep Dive

Neurocrine Biosciences Ingrezza (valbenazine) tardive dyskinesia franchise + selected post-December 2024 CRENESSITY (crinecerfont) congenital adrenal hyperplasia launch represent selected primary strategic differentiation thesis vs traditional neuroscience + endocrinology pharmaceutical peers (Teva + selected various Vertex Pharmaceuticals + Alnylam + selected various). Selected ~$2.30-2.45B aggregate Ingrezza revenue FY2025 (~90%+ aggregate revenue mix; selected primary tardive dyskinesia + Huntington's chorea VMAT2 inhibitor) + selected continued post-2024 ~+15-20% YoY Ingrezza revenue growth + selected continued post-2024 selected primary US tardive dyskinesia leadership (selected ~50%+ aggregate US tardive dyskinesia market share) + selected post-April 2017 Ingrezza FDA approval for tardive dyskinesia (selected first VMAT2 inhibitor approved for tardive dyskinesia) supports selected primary Ingrezza tardive dyskinesia franchise thesis. Selected post-December 2024 ~$60-100M aggregate CRENESSITY (crinecerfont) FDA approval (selected first-in-class novel pediatric + adult congenital adrenal hyperplasia treatment) + selected continued post-December 2024 selected various Q1 2026 commercialization launch + selected continued post-2024 ~$200-400M aggregate FY2026 CRENESSITY revenue expectation + selected continued post-2024 ~$0.40-0.60 incremental annual EPS contribution from selected various CRENESSITY launch supports selected primary CRENESSITY pediatric + adult CAH franchise thesis. Selected modest opportunistic buybacks + selected ~$300-500M aggregate FY2024-2025 buyback program + selected ~$200-300M aggregate FY2025 capital return + selected post-2024 ~$1.6-1.9B aggregate cash + investments balance + selected ~$0M aggregate net debt position + selected pathway to dividend initiation FY2026-2027 supports selected continued post-2024 capital flexibility. Selected post-April 2024 Kyle Gano CEO appointment (selected ex-Neurocrine COO 2017-2024 + ~25-year company career) supports selected continued post-April 2024 strategic priorities. FY2026 catalyst: continued Ingrezza + CRENESSITY + ~$1.0-1.5 incremental annual EPS contribution.

FY2026 thesis: Ingrezza tardive dyskinesia franchise + CRENESSITY pediatric + adult CAH launch + ~50%+ aggregate US tardive dyskinesia market share leadership + ~$1.6-2.2B aggregate cash + investments balance + selected ~$0M aggregate net debt + ~$200-400M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027.

Related:NBIX

Want deeper analysis?

Ask drillr anything about NBIX — powered by SEC filings, earnings calls, and real-time data.

Try drillr.ai for free